Related Experiment Videos
Preoperative chemotherapy for mesoblastic nephroma
Medical and Pediatric Oncology
|April 1, 1995
Summary
Neoadjuvant vincristine chemotherapy effectively shrank an advanced stage III mesoblastic nephroma in a neonate, enabling safe surgical removal. This approach facilitated a successful nephrectomy, preventing recurrence one year post-operation.
Area of Science:
- Pediatric Oncology
- Surgical Oncology
- Medical Imaging
Background:
- Mesoblastic nephroma is a rare congenital kidney tumor, often presenting at an advanced stage.
- Extensive stage III mesoblastic nephroma poses surgical challenges due to tumor infiltrative nature.
- Primary tumor excision is often not feasible for advanced-stage disease.
Observation:
- A neonate presented with extensive stage III mesoblastic nephroma, deemed inoperable at initial surgery.
- The patient received neoadjuvant chemotherapy with vincristine (1.1 mg/m2 weekly for 8 doses).
- Post-chemotherapy imaging (CT scan) demonstrated significant tumor shrinkage.
Findings:
- Neoadjuvant vincristine chemotherapy enabled a safe and complete nephrectomy during a second laparotomy.
- Histopathological confirmation of tumor removal was achieved.
- Follow-up CT scan at 1 year showed no evidence of tumor recurrence.
Implications:
- Single-agent neoadjuvant chemotherapy can be an effective strategy for managing extensive stage III mesoblastic nephroma.
- This approach allows for potentially curative surgical intervention in cases initially deemed unresectable.
- Vincristine chemotherapy represents a viable option to improve surgical outcomes in pediatric renal tumors.